Cart
sales@molnova.com
ADR-925
CAS No. 75459-34-6
ADR-925( —— )
Catalog No. M34491 CAS No. 75459-34-6
ADR-925, an active chelated iron metabolite of dexrazoxane, has the ability to protect neonatal rat cardiomyocytes from doxorubicin-induced injury.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 2138 | In Stock |
|
| 10MG | 2822 | In Stock |
|
| 25MG | 4266 | In Stock |
|
| 50MG | 5552 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameADR-925
-
NoteResearch use only, not for human use.
-
Brief DescriptionADR-925, an active chelated iron metabolite of dexrazoxane, has the ability to protect neonatal rat cardiomyocytes from doxorubicin-induced injury.
-
DescriptionADR-925, an active chelated iron metabolite of dexrazoxane, has the ability to protect neonatal rat cardiomyocytes from doxorubicin-induced injury.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayProteasome/Ubiquitin
-
TargetEndogenous Metabolite
-
RecptorEndogenous Metabolite
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number75459-34-6
-
Formula Weight304.3
-
Molecular FormulaC11H20N4O6
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESN([C@H](CN(CC(N)=O)CC(O)=O)C)(CC(N)=O)CC(O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Diphenyl disulfide
Diphenyl disulfide (Phenyl disulfide) shows anticancer activity in breast cancer cell lines.Diphenyl disulfide induces and enhances apoptosis in breast cancer cells through Bax protein hydrolysis activation and concomitant autophagy.
-
DCBA
DCBA is a metabolite of insect repellent N-N-diethyl-meta-toluamide (DEET).
-
Glucagon-Like Peptid...
Glucagon-like peptide 2 (GLP-2) is a recently identified intestinal epithelium-specific growth factor that has been shown to reduce the severity of inflammatory disorders of the intestine in rodent models. Currently Glucagon-Like Peptide 2 is used as a potential therapeutic agent for the human subjects with a broad variety of intestinal diseases characterized by intestinal damage and insufficiency.
